27.12.2012 Views

Complaint Counsel's Post Trial Brief - Federal Trade Commission

Complaint Counsel's Post Trial Brief - Federal Trade Commission

Complaint Counsel's Post Trial Brief - Federal Trade Commission

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

would not recommend that people self-medicate with herbal remedies in treating cancer, and that<br />

he was sure there was a risk some people wil pursue herbal medications instead of effective<br />

pharaceutical medications and thereby die. CCPF iM 244-45, 292. Duke reviewed the<br />

literature and information regarding Respondents' products and found no evidence that those<br />

products, or their ingredients, had been shown in clinical trals to be effective in the treatment of<br />

cancer. CCPF iM 381-82,396-402,436-42. Indeed, to the contrar, Duke stated that the studies<br />

he had reviewed on the pricipal ingredients in two of Respondents' products - shark carlage<br />

(Bio*Shark) and essaic tea (7 Herb Formula) - questioned their effcacy in treating cancer.<br />

CCPF iM 381-82,402. At tral, Duke also testified that he was "quite surrised" that most of the<br />

chemcals in the plants used in the DCO Products "are not biblical." CCPF ~ 256.<br />

LaMont testified that "cancer must be treated with conventional therapies." CCPF ~ 333.<br />

LaMont stated that if in the course of doing a work -up on a patient, she found "a diagnosis that<br />

looks like it could be cancer," she absolutely would refer the patient to a traditional physician<br />

and would co-manage that patient's care with the physician. CCPF ~ 328. She ths that it is<br />

"best that people follow the recommendations of<br />

their oncologist and utilize protocols that are<br />

proven to be most effective for their cancer and that they should be well-informed ofthe<br />

potential value of<br />

the aray of other therapies." CCPF ~ 355. She added that "(t)he awareness of<br />

the powerl chemoprotective effects of plant foods and medicines should not influence patients<br />

with cancer and other serous disease to abandon using the most effective methods that moder<br />

medicine has to offer." CCPF ~ 357.<br />

LaMont also testified that there have been no clincal studies perormed on the DCO<br />

Products, and stated that these products "are not silver bullets." CCPF iM 352-53. LaMont<br />

acknowledged that since the DCO products have not been tested, we do not know the<br />

30

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!